ABBV-744 is primarily utilized in the field of oncology, specifically targeting cancers that are driven by the overexpression of BET proteins. It functions as a selective inhibitor of the BD2 domain within BET proteins, which plays a crucial role in regulating gene expression related to cancer cell growth and survival. This selectivity allows ABBV-744 to potentially reduce off-target effects compared to pan-BET inhibitors, making it a promising candidate for treating hematologic malignancies such as acute myeloid leukemia (AML) and multiple myeloma. Its application is currently under investigation in clinical trials to assess its efficacy and safety in patients with these types of cancers.